Gain Therapeutics, Inc. has announced the appointment of Jeanette Weidner as Vice President of Finance, effective October 28, 2026. In this role, Ms. Weidner will also serve as the Company’s principal financial officer and principal accounting officer.
Ms. Weidner, 44, brings 18 years of experience in accounting and finance, including over a decade in the life sciences sector. Prior to joining Gain Therapeutics, she was a financial consultant at Senseonics Holdings Inc. (Nasdaq: SENS) from March 2025 to October 2026. Earlier in her career, she served as Vice President, Finance for OncoC4, Inc., where she led the accounting and finance function from the company's inception through Phase III clinical trials.
The Company has entered into an employment agreement with Ms. Weidner. Under the agreement, she is entitled to an annual base salary of $275,000. She is also eligible for an annual incentive cash bonus, initially set at a target of 35% of her base salary, as determined by the Board of Directors.
Ms. Weidner will receive an option to purchase up to 130,000 shares of the Company’s common stock under the 2022 Equity Incentive Plan. This option will vest over a four-year period, with 25% vesting on the first anniversary of the Effective Date and the remainder vesting in equal monthly installments, subject to her continued employment.
The agreement outlines severance terms in the event of termination. If the Company terminates her employment without cause after three months, she is eligible for six months of base salary in cash. If termination occurs due to a Change of Control or within 12 months thereafter, she would receive 12 months of base salary, a pro-rated annual cash bonus, and accelerated vesting of unvested stock awards.
